{"id":72311,"date":"2026-10-01T00:00:04","date_gmt":"2026-09-30T16:00:04","guid":{"rendered":"https:\/\/naipnews.naipo.com\/?p=72311"},"modified":"2026-10-01T00:23:03","modified_gmt":"2026-09-30T16:23:03","slug":"uspto%e6%8c%87%e5%ae%9aex-parte-baurin%e6%a1%88arp%e5%86%b3%e5%ae%9a%e4%bd%9cotdp%e5%85%88%e4%be%8b%e6%84%8f%e8%a7%81","status":"publish","type":"post","link":"https:\/\/naipnews.naipo.com\/zh-hans\/72311\/","title":{"rendered":"USPTO\u6307\u5b9aEx parte Baurin\u6848ARP\u51b3\u5b9a\u4f5cOTDP\u5148\u4f8b\u610f\u89c1"},"content":{"rendered":"<p><strong>\u9ec4\u5170\u95f5\uff0f\u5317\u7f8e\u667a\u6743\u3000\u667a\u6743\u6cd5\u89c4\u7814\u7a76\u5458<\/strong><\/p>\n<blockquote><p>USPTO\u72ed\u4e49\u89e3\u91caFed. Cir. <em>Allergan<\/em>\u6848\u4f8b\u5916\u539f\u5219\uff0c\u6307\u793a\u8be5\u5c40\u4eba\u5458\u6309MPEP 804\u5904\u7406\u663e\u800c\u6613\u89c1\u578b\u91cd\u590d\u6388\u6743\uff08OTDP\uff0c\u5373\u975e\u6cd5\u5b9a\u91cd\u590d\u6388\u6743\uff0cNSDP\uff09\u95ee\u9898\u3002<\/p><\/blockquote>\n<p>2026\u5e743\u6708USPTO\u5c40\u957fJohn A. Squires\u518d\u5ea6\u542f\u52a8\u8bc9\u613f\u590d\u5ba1\u5c0f\u7ec4\uff08Appeals Review Panel\uff0c\u7b80\u79f0ARP\uff09\u673a\u5236\uff0c\u4ecb\u5165<em>Ex parte Baurin<\/em>\u8bc9\u613f\u6848\u7a0b\u5e8f\u3002<a href=\"#_ftn1\" name=\"_ftnref1\">[1]<\/a>\u7ecf\u8fc7\u6570\u6708\u6d88\u5316\u5404\u65b9\u610f\u89c1\uff0c2026\u5e748\u67086\u65e5USPTO\u516c\u544a<em>Ex parte Baurin<\/em>, Appeal 2024-002920 (ARP Aug. 6, 2026)\uff0c\u91cd\u65b0\u91c7\u8ba4\u5ba1\u67e5\u5b98\u539f\u663e\u800c\u6613\u89c1\u578b\u91cd\u590d\u6388\u6743\uff08obviousness-type double patenting\uff0c\u7b80\u79f0OTDP\uff09<a href=\"#_ftn2\" name=\"_ftnref2\">[2]<\/a>\u6838\u9a73\u5904\u5206\uff0c\u5e76\u6307\u5b9a\u8be5\u6848ARP\u51b3\u5b9a\u4f5cOTDP\u5148\u4f8b\u610f\u89c1<a href=\"#_ftn3\" name=\"_ftnref3\">[3]<\/a>\uff1a\u9664\u975e\u786e\u8ba4\u6070\u662f\u7f8e\u56fd\u8054\u90a6\u5de1\u56de\u4e0a\u8bc9\u6cd5\u9662\uff08United States Court of Appeals for the Federal Circuit\uff1b\u7b80\u79f0Fed. Cir.\u6216CAFC\uff09<em>Allergan<\/em>\u6848<a href=\"#_ftn4\" name=\"_ftnref4\">[4]<\/a>\u6559\u793a\u9002\u7528\u6001\u6837\uff0cUSPTO\u4eba\u5458\u4ecd\u5e94\u6309<em>Allergan<\/em>\u6848\u5ba3\u5224\u524d\u65e2\u6709\u7684MPEP 804\u63ed\u793a\u539f\u5219\u5904\u7406\u3002<\/p>\n<p>\u672c\u6848ARP\u51b3\u5b9a\u516c\u544a\u540e\uff0c\u8bb8\u591a\u4e13\u5bb6\u90fd\u53d1\u6587\u8bc4\u8bba\u5206\u6790\u3002\u4e00\u822c\u4ee5\u4e3a\uff0cUSPTO\u5bf9<em>Allergan<\/em>\u6848\u6559\u793a\u4f5c\u76f8\u5bf9\u72ed\u4e49\u7684\u89e3\u8bfb\uff0c\u4e13\u5229\u4ece\u4e1a\u4eba\u5458\u7814\u62df\u7533\u8bf7\u7b56\u7565\u53ca\u89c4\u753b\u4e13\u5229\u7ec4\u5408\u65f6\uff0c\u4ecd\u5e94\u4f9d\u5faaMPEP 804\u53ca\u672c\u6848ARP\u610f\u89c1\u53cd\u6620\u7684USPTO\u73b0\u884c\u4f5c\u4e1a\u539f\u5219\uff0c\u540c\u65f6\u5b9c\u518d\u6ce8\u610f<em>In re Ablynx<\/em>\u6848\u53d1\u5c55\u3002<a href=\"#_ftn5\" name=\"_ftnref5\">[5]<\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_69_1 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">\u76ee\u9304<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 eztoc-toggle-hide-by-default' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/naipnews.naipo.com\/zh-hans\/72311\/#%E6%A1%88%E4%BB%B6%E8%83%8C%E6%99%AF\" title=\"\u6848\u4ef6\u80cc\u666f\">\u6848\u4ef6\u80cc\u666f<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/naipnews.naipo.com\/zh-hans\/72311\/#ARP%E5%86%B3%E5%AE%9A\" title=\"ARP\u51b3\u5b9a\">ARP\u51b3\u5b9a<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/naipnews.naipo.com\/zh-hans\/72311\/#%E6%9C%AA%E6%9D%A5%E5%AE%A1%E6%9F%A5%E5%8F%AF%E8%83%BD%E6%A1%86%E6%9E%B6%E6%8F%90%E8%AE%AE\" title=\"\u672a\u6765\u5ba1\u67e5\u53ef\u80fd\u6846\u67b6\u63d0\u8bae\">\u672a\u6765\u5ba1\u67e5\u53ef\u80fd\u6846\u67b6\u63d0\u8bae<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"%E6%A1%88%E4%BB%B6%E8%83%8C%E6%99%AF\"><\/span><strong>\u6848\u4ef6\u80cc\u666f<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>\u672c\u8bc9\u613f\u6848\u76ee\u6807\u4e3a2020\u5e7412\u670828\u65e5\u63d0\u4ea4\u7684\u7533\u8bf7\u684817\/135,529\uff0c\u76ee\u524d\u5f52Sanofi\u6240\u6709\uff0c\u56e0\u4e3b\u5f20\u7684\u6700\u65e9\u7f8e\u56fd\u6b63\u5f0f\u6848\u4f18\u5148\u6743\u6848\u662f2012\u5e743\u670828\u65e5\u7533\u8bf7\uff0c\u4e14\u63d0\u4ea4\u8fc7\u4e24\u4efdTD\uff0c\u56e0\u6b64\uff0c\u5018\u80fd\u6388\u6743\uff0c\u5176\u4e13\u5229\u6743\u671f\u95f4\u4e00\u5b9a\u4f1a\u57282032\u5e743\u670828\u65e5\u4e4b\u524d\u7ed3\u675f\u3002\u539f\u5ba1\u67e5\u5b98\u5bf9\u8be5\u6848\u76841-18\u9879\u8bf7\u6c42\u9879\u5168\u90fd\u53d1\u51faOTDP\u6838\u9a73\uff0c\u5f15\u8bc1\u6848\u5305\u542b\u540e\u7533\u8bf7\u4e14\u540e\u5c4a\u671f\u6d88\u706d\u7684\u7f8e\u56fd\u4e13\u522910,882,922\uff0c\u8be5\u4e13\u5229\u540c\u4e3aSanofi\u6240\u6709\uff0c\u4e13\u5229\u6743\u671f\u95f4\u57282037\u5e74\u624d\u4f1a\u7ed3\u675f\u3002\u6362\u8a00\u4e4b\uff0c\u76ee\u6807\u7533\u8bf7\u684817\/135,529\u5373\u4f7f\u51c6\u8bc1\u6388\u6743\uff0c\u76f8\u5bf9\u5f15\u8bc1\u4e13\u522910,882,922\uff0c\u5e76\u65e0\u4e0d\u5f53\u5ef6\u957f\u72ec\u5360\u671f\u95f4\u7684\u95ee\u9898\uff0c\u4e0d\u8fc7\u5ba1\u67e5\u5b98\u4ecd\u53d1OTDP\u6838\u9a73\uff0c\u7406\u7531\u662f17\/135,529\u82e5\u51c6\u4e88\u6388\u6743\uff0c\u65e5\u540e\u6709\u53ef\u80fd\u4e0e\u5f15\u8bc1\u4e13\u522910,882,922\u5206\u522b\u4e3a\u4e0d\u540c\u5b9e\u4f53\u6240\u62e5\u6709\uff08anti-harassment (multiple assignee harassment) rationale\uff0c\u907f\u514d\u91cd\u590d\u9a9a\u6270\u4e8b\u7531\uff09\u3002<\/p>\n<p>\u7533\u8bf7\u4eba\u4e3a\u6b64\u5411PTAB\u63d0\u51fa\u8bc9\u613f\uff0c<em>Allergan<\/em>\u6848\u5ba3\u5224\u540e\uff0cPTAB\u4e8e2024\u5e7411\u670828\u65e5\u53d1\u5e03\u4e66\u9762\u51b3\u5b9a\uff0c\u8ba4\u5b9a10,882,922\u4e0d\u662f\u9002\u683c\u5f15\u8bc1\u6848\uff0c\u6545\u64a4\u9500\u539f\u5ba1\u67e5\u5b98\u8be5OTDP\u6838\u9a73\u5904\u5206\u30022025\u5e741\u67083\u65e5\uff0c\u539f\u5ba1\u67e5\u5b98\u63d0Rehearing\u8bf7\u6c42\uff0c\u6307PTAB\u524d\u8ff0\u8bc9\u613f\u51b3\u5b9a\u9519\u8bef\u5957\u7528<em>Allergan<\/em>\u6848\u5224\u4f8b\u539f\u5219\uff0c17\/135,529\u82e5\u51c6\u4e88\u6388\u6743\uff0c\u53ef\u80fd\u884d\u751f\u4e0e\u5176\u5f15\u8bc1\u6848\u5206\u522b\u4e3a\u4e0d\u540c\u5b9e\u4f53\u6301\u6709\u7684\u98ce\u9669\uff0c\u4e14\u8fdd\u80ccMPEP 804\u53ca804.02\u6240\u8ff0\u653f\u7b56\uff0c\u76fc\u80fd\u518d\u8bae\u3002<\/p>\n<p>2025\u5e7412\u670818\u65e5\uff0cPTAB\u4e09\u4eba\u5408\u8bae\u5c0f\u7ec4\u53d1\u5e03Rehearing\u51b3\u5b9a\uff0c\u4ee52-1\u7684\u7968\u6570\u9a73\u56de\u5ba1\u67e5\u5b98\u8bf7\u6c42\uff0c\u8ba4\u5b9a\u539f\u51b3\u5b9a\u5e76\u65e0\u9519\u8bef\u3002\u5176\u591a\u6570\u610f\u89c1\u6307\u51fa\uff0c17\/135,529\u82e5\u6388\u6743\u516c\u544a\uff0c\u4e0d\u4f1a\u5ef6\u957f\u6240\u8bf7\u53d1\u660e\u53ca10,882,922\u4e13\u5229\u72ec\u5360\u671f\u95f4\uff0c\u572810,882,922\u4e0d\u662f\u9002\u683cODP\u5f15\u8bc1\u6848\u7684\u60c5\u51b5\u4e0b\uff0c\u5206\u522b\u4e3a\u4e0d\u540c\u5b9e\u4f53\u6240\u62e5\u6709\u7684\u98ce\u9669\u65e0\u5173\u5b8f\u65e8\uff08immaterial\uff09\uff1b\u800c<em>Fallaux<\/em>\u4e00\u6848<a href=\"#_ftn6\" name=\"_ftnref6\">[6]<\/a>\uff0cFed. Cir.\u610f\u89c1\u4e66\u867d\u79f0\u907f\u514d\u91cd\u590d\u9a9a\u6270\u4e8b\u7531\u5728\u8be5\u6848\u5c24\u5176\u76f8\u5173\uff0c\u4f46\u5176\u5224\u51b3\u5176\u5b9e\u65e0\u987b\u5c31\u6b64\u72ec\u7acb\u8bae\u9898\u53e6\u5916\u6df1\u5165\u63a2\u8ba8\uff0c\u6700\u591a\u53ea\u80fd\u89c6\u4f5c\u9644\u5e26\u610f\u89c1\uff08dicta\uff09\u3002\u81f3\u4e8eMPEP\u6240\u8f7d\u89c4\u8303\uff0c\u610f\u89c1\u4e66\u76f4\u6307MPEP\u4e0d\u80fd\u81ea\u884c\u521b\u9020\u65b0\u6cd5\u3001\u65e0\u89c6\u6cd5\u5f8b\u89c4\u5b9a\u3002<\/p>\n<p>\u53ea\u4e0d\u8fc7\uff0cUSPTO\u5c40\u957f\u5bf9\u6b64\u89c1\u89e3\u663e\u7136\u62b1\u6301\u7591\u8651\uff0c2026\u5e743\u67085\u65e5\u5ba3\u5e03\u542f\u52a8ARP\u673a\u5236\u4e3b\u52a8\u4ecb\u5165\u3002<\/p>\n<h2><span class=\"ez-toc-section\" id=\"ARP%E5%86%B3%E5%AE%9A\"><\/span><strong>ARP\u51b3\u5b9a<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>\u672c\u6848\u6700\u7ec8\u7684ARP\u51b3\u5b9a\u662f\u7531USPTO\u5c40\u957f\u4eb2\u81ea\u5177\u540d\u4e66\u5199\u3002\u8ba8\u8bba\u91cd\u590d\u6388\u6743\u95ee\u9898\u65f6\uff0c\u6bd4\u5bf9\u7684\u662f\u4e24\u6848\uff08\u7533\u8bf7\uff09\u4e13\u5229\u8303\u56f4\uff0c\u800c\u4f9d\u5176\u6574\u7406\uff0c<em>Allergan<\/em>\u6848\u6838\u5fc3\u539f\u5219\u4e3a\uff1a<u>\u6700\u65e9\u7533\u8bf7<\/u>\u4e14<u>\u6700\u65e9\u6388\u6743<\/u>\u4f46\u8f83\u665a\u5230\u671f\u8005\uff0c\u5373\u4f7f<u>\u540c\u4f18\u5148\u6743\u65e5<\/u>\u6709\u8f83\u665a\u7533\u8bf7\u4e14\u8f83\u665a\u6388\u6743\u4f46\u8f83\u65e9\u5230\u671f\u7684\u5f15\u8bc1\u6848\uff0c\u4e0d\u56e0\u6b64\u65e0\u6548\uff08a <u>first-filed<\/u>, <u>first-issued<\/u>, later-expiring claim cannot be invalidated by a later-filed, later-issued, earlier-expiring reference claim having a <u>common priority date<\/u>.\uff09\u3002<\/p>\n<p>\u5c3d\u7ba1\u8bc9\u613f\u4eba\u53ca\u591a\u6570\u516c\u4f17\u610f\u89c1\u8d5e\u6210\u5e7f\u5f00\u751f\u95e8\u3001\u4ece\u5bbd\u89e3\u91ca<em>Allergan<\/em>\u6848\u6559\u793a\uff0c\u4f46ARP\u5224\u65ad\u7ed3\u679c\u662f\uff0c\u672c\u6848\u5e76\u4e0d\u9002\u7528<em>Allergan<\/em>\u6848\u7684OTDP\u4f8b\u5916\u6761\u6b3e\uff1a\u4e00\u6765\uff0c\u672c\u6848\u8bc9\u613f\u76ee\u6807\u7533\u8bf7\u684817\/135,529\uff0c\u5e76\u4e0d\u662f\u6240\u5c5e\u4e13\u5229\u5bb6\u65cf\u6700\u65e9\u9001\u4ef6\u7684\u7533\u8bf7\u6848\uff1b\u4e8c\u5219\uff0c\u65e2\u4ecd\u7cfb\u5c5e\uff08Pending\uff09\u4e8eUSPTO\u7a0b\u5e8f\uff0c\u4e5f\u4e0d\u662f\u6700\u65e9\u6388\u6743\u7684\u4e00\u4ef6\uff1b\u7b2c\u4e09\uff0c\u4e0e10,882,922\u6709\u4e0d\u540c\u7684\u4e13\u5229\u6743\u671f\u95f4\u7533\u8bf7\u65e5\uff08Patent Term Filing Date\uff09<a href=\"#_ftn7\" name=\"_ftnref7\">[7]<\/a>\u3002<\/p>\n<p>\u5176\u610f\u89c1\u4e66\u5e76\u591a\u6b21\u63f4\u5f15\u540c\u6837\u65e0\u4e0d\u5f53\u5c55\u5ef6\u72ec\u5360\u671f\u95f4\u95ee\u9898\u7684<em>Fallaux<\/em>\u7b49\u6848\uff0c\u636e\u4ee5\u8bc1\u660e\u91cd\u590d\u9a9a\u6270\u98ce\u9669\u4e5f\u662f\u6cd5\u9662\u8ba4\u8bc1\u7684\u7591\u8651\uff0c\u5373\u4fbf\u5982PTAB\u548c\u8bc9\u613f\u4eba\u6240\u8a00\uff0c<em>Fallaux<\/em>\u7b49\u6848\u63d0\u907f\u514d\u91cd\u590d\u9a9a\u6270\u7684\u6587\u5b57\uff0c\u53ea\u80fd\u7b97\u9644\u5e26\u610f\u89c1\uff0c\u4f46\u8fd8\u662f\u4e00\u79cd\u80af\u8ba4\u3002ARP\u51b3\u5b9a\u5e76\u5199\u660e\uff0c\u4e07\u4e00\u771f\u662f\u9519\u89e3Fed. Cir.\u610f\u89c1\uff0c\u76f8\u5173\u5224\u4f8b\u4e0d\u5e94\u89e3\u91ca\u4f5c\u53ef\u5355\u72ec\u4ee5\u907f\u514d\u91cd\u590d\u9a9a\u6270\u4e8b\u7531\u5236\u53d1OTDP\u6838\u9a73\uff0c<em>In re: Ablynx N.V.<\/em>\u6848\uff08Fed. Cir. Case No. 26-1333\uff09\u5df2\u6392\u5165Fed. Cir.\u5ba1\u7406\u540d\u5355\uff0c\u6b22\u8fceFed. Cir.\u518d\u4e88\u6f84\u6e05\u3002<\/p>\n<p>\u6709\u9274\u4e8e\u6b64\uff0c\u4f9d\u5176ARP\u610f\u89c1\u4e66\u5185\u6307\u793a\uff0c\u9664\u975e\u5224\u65ad\u6848\u4ef6\u5f62\u6001\u53ef\u9002\u7528<em>Allergan<\/em>\u6848\u6559\u793a\u7684\u4f8b\u5916\u539f\u5219\uff0c\u5426\u5219USPTO\u4eba\u5458\u5e94\u7ee7\u7eed\u4f9dMPEP 804\u5236\u53d1OTDP\u6838\u9a73\u3002\u800c\u8981\u9002\u7528<em>Allergan<\/em>\u6848\u6559\u793a\u7684\u4f8b\u5916\u539f\u5219\uff0c\u5fc5\u987b\u6ee1\u8db3\u4ee5\u4e0b\u4e24\u5927\u6761\u4ef6\uff1a\u2474\u5ba1\u67e5\u4e2d\u6848\u4ef6\u4e0e\u53ef\u80fdOTDP\u5f15\u8bc1\u6848\u7cfb\u51fa\u540c\u95e8\uff0c\u5c5e\u540c\u4e00\u4e13\u5229\u5bb6\u65cf\uff0c\u6709\u540c\u6837\u7684\u4e13\u5229\u6743\u671f\u95f4\u7533\u8bf7\u65e5\uff1b\u4e14\u2475\u5ba1\u67e5\u4e2d\u6848\u4ef6\u662f\u8be5\u4e13\u5229\u5bb6\u65cf\u4e2d\uff0c\u6700\u65e9\u9001\u4ef6\u7533\u8bf7\u3001\u6700\u65e9\u6388\u6743\uff0c\u53ea\u4e0d\u8fc7\u8f83\u665a\u5230\u671f\u3002<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%E6%9C%AA%E6%9D%A5%E5%AE%A1%E6%9F%A5%E5%8F%AF%E8%83%BD%E6%A1%86%E6%9E%B6%E6%8F%90%E8%AE%AE\"><\/span><strong>\u672a\u6765\u5ba1\u67e5\u53ef\u80fd\u6846\u67b6\u63d0\u8bae<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>\u5c3d\u7ba1ARP\u610f\u89c1\u4e66\u6307\u79f0\uff0cFed. Cir.\u5224\u4f8b\u652f\u6301\u53ef\u5355\u72ec\u4ee5\u907f\u514d\u91cd\u590d\u9a9a\u6270\u4e3a\u7531\u5236\u53d1OTDP\u6838\u9a73\uff0c\u7136\u800c\u4e0d\u53ef\u5426\u8ba4\uff0c\u8fd9\u4e00\u903b\u8f91\u6a21\u5f0f\u6709\u5176\u6f5c\u5728\u95ee\u9898\uff1a\u5728\u4e24\u6848\u5b9e\u9645\u5f52\u5c5e\u4e0d\u540c\u5b9e\u4f53\u4e14\u6709\u91cd\u590d\u9a9a\u6270\u60c5\u4e8b\u53d1\u751f\u4e4b\u524d\uff0c\u4e00\u5207\u7eaf\u4e3a\u81c6\u6d4b\uff1b\u4ee5\u6b64\u81c6\u6d4b\u7528\u4f5c\u6838\u9a73\u6216\u65e0\u6548\u4e8b\u7531\uff0c\u53ef\u80fd\u4e3a\u540e\u7eed\u521b\u65b0\u6216\u8de8\u5b9e\u4f53\u7814\u7a76\u5408\u4f5c\u589e\u52a0\u963b\u529b\u3001\u524a\u5f31\u5176\u52a8\u673a\uff1b\u4e14\u5982ARP\u610f\u89c1\u4e66\u4e3e\u4f8b\u8bf4\u660e\uff0c\u4e0d\u6392\u9664\u4f1a\u6709\u7533\u8bf7\u4eba\u9762\u4e34\u65e0\u6cd5\u8131\u8eab\u7684\u56f0\u5883\u3002<a href=\"#_ftn8\" name=\"_ftnref8\">[8]<\/a><\/p>\n<p>\u4e8e\u662f\uff0cARP\u610f\u89c1\u4e66\u4e5f\u4ee5\u9887\u957f\u7bc7\u5e45\u8ba8\u8bba\uff0c\u4e07\u4e00\uff0cFed. Cir.\u5229\u7528<em>Ablynx<\/em>\u6848\u6216\u6709\u5176\u4ed6\u6848\u4ef6\uff0c\u786e\u8ba4\u4e0d\u80fd\u4ec5\u4ee5\u907f\u514d\u91cd\u590d\u9a9a\u6270\u4e3a\u7531\u5236\u53d1OTDP\u6838\u9a73\uff0c\u4e3a\u65b9\u4fbf\u5ba1\u67e5\u5b98\u64cd\u4f5c\u53ca\u5229\u5bb3\u5173\u7cfb\u4eba\u9884\u5224\uff0cARP\u610f\u89c1\u4e66\u4e5f\u8bd5\u62df\u672a\u6765\u5ba1\u67e5\u7684\u53ef\u80fd\u6846\u67b6\uff08\u6b64\u4e00\u53ef\u80fd\u6846\u67b6\u672a\u6765\u662f\u5426\u771f\u4e88\u5b9e\u884c\uff0c\u89c6Fed. Cir.\u5bf9OTDP\u8fd9\u7c7b\u6838\u9a73\u7684\u6001\u5ea6\u800c\u5b9a\uff09\uff1a<\/p>\n<table>\n<tbody>\n<tr>\n<td width=\"64\"><strong>\u4e24\u6848<\/strong><\/td>\n<td width=\"319\"><strong>\u5206\u5c5e\u4e24\u4e2a\u4e13\u5229\u5bb6\u65cf<\/strong><\/td>\n<td width=\"319\"><strong>\u540c\u5c5e\u4e00\u4e2a\u4e13\u5229\u5bb6\u65cf<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"64\"><strong>\u6bd4\u5bf9\u65e5<\/strong><\/td>\n<td width=\"319\">\u4e13\u5229\u6743\u671f\u95f4\u7533\u8bf7\u65e5<\/td>\n<td width=\"319\">\u5b9e\u9645\u7533\u8bf7\u65e5\uff08\u53ca\u6388\u6743\u65e5\uff09<\/td>\n<\/tr>\n<tr>\n<td width=\"64\"><strong>\u8bf4\u660e<\/strong><\/td>\n<td width=\"319\">\u53ef\u80fdOTDP\u5f15\u8bc1\u6848\u6bd4\u5bf9\u65e5\u665a\u4e8e\u5ba1\u67e5\u4e2d\u6848\u4ef6\uff1f<\/p>\n<p>-\u82e5\u662f\uff0c\u505c\u6b62\u76f8\u5173\u5206\u6790<\/p>\n<p>\uff08\u9664\u975e\u6848\u5377\u8bb0\u5f55\u660e\u793a\u7279\u6b8a\u60c5\u51b5\uff1a\u4f8b1\uff0c\u8be5\u53ef\u80fdOTDP\u5f15\u8bc1\u6848\u6709TD\uff0c\u5ba1\u67e5\u4e2d\u7533\u8bf7\u684820\u5e74\u57fa\u672c\u4e13\u5229\u6743\u671f\u95f4\u4f1a\u8d85\u51fa\u5176\u5230\u671f\u65e5\uff1b\u4f8b2\uff0c\u5ba1\u67e5\u4e2d\u6848\u4ef6\u662f\u9886\u8bc1\u4e13\u5229\uff0c\u6388\u6743\u65f6\u6709\u786e\u5b9a\u7684PTA\u5929\u6570\uff09<\/p>\n<p>-\u82e5\u5426\uff0c\u7ee7\u7eed\u6bd4\u5bf9\u4e24\u6848\uff08\u7533\u8bf7\uff09\u4e13\u5229\u8303\u56f4\uff0c\u5224\u65ad\u662f\u5426\u5e94\u53d1OTDP\u6838\u9a73<\/td>\n<td width=\"319\">\u5b9e\u9645\u7533\u8bf7\u65e5\u8f83\u665a\u8005\uff0c\u53ef\u62ff\u540c\u5bb6\u65cf\u5b9e\u9645\u7533\u8bf7\u65e5\u8f83\u65e9\u7684\u6bcd\u6848\u6216\u5176\u4ed6\u5148\u7533\u8bf7\u6848\u53d1OTDP\u6838\u9a73\uff1b\u53cd\u4e4b\u5219\u5426<\/td>\n<\/tr>\n<tr>\n<td width=\"64\"><strong>\u5907\u6ce8<\/strong><\/td>\n<td width=\"319\">\u4ec5\u6839\u636e\u5ba1\u67e5\u4e2d\u6848\u4ef6\u5b98\u65b9\u6848\u5377\u8bb0\u5f55\u7684\u5df2\u77e5\u4e8b\u5b9e\uff0c\u4e0d\u5984\u81ea\u9884\u6d4b\u5176\u672a\u77e5\u3002\u6240\u8c13\u672a\u77e5\uff0c\u4f8b\u5982\u7533\u8bf7\u6848\u6388\u6743\u540e\u53ef\u80fd\u4ea7\u751fPTA\u3001\u8fd8\u6709\u673a\u4f1a\u64a4\u56deTD\u3001\u4ee5\u540e\u53ef\u80fd\u53d8\u66f4\u7f8e\u56fd\u56fd\u5185\u4f18\u5148\u6743\u4e3b\u5f20<\/td>\n<td width=\"319\">\u4e00\u822c\u6bd4\u5bf9\u4e24\u6848\u5b9e\u9645\u7533\u8bf7\u65e5\uff0c\u82e5\u5df2\u77e5\u6388\u6743\u65e5\uff0c\u4e5f\u52a0\u4ee5\u8003\u8651<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<p>\u81f3\u4e8e\u91cd\u590d\u9a9a\u6270\u98ce\u9669\uff0c\u5982\u679c\u786e\u8ba4\u53ef\u5355\u72ec\u4ee5\u6b64\u4e3a\u7531\u5236\u53d1OTDP\u6838\u9a73\uff0c\u4e3a\u964d\u4f4e\u5176\u6f5c\u5728\u526f\u4f5c\u7528\uff0cARP\u610f\u89c1\u4e66\u4e5f\u5217\u51fa\u4e24\u79cd\u53ef\u80fd\u7684\u51cf\u707e\u5904\u7406\u6a21\u5f0f\uff1a\u4e00\u662f\u9009\u62e9\u6027\u6267\u884c\uff0c\u8b6c\u5982\uff0c\u4ec5\u9488\u5bf9\u8bc1\u636e\u663e\u793a\u66fe\u6709\u62c6\u5206\u884c\u4e3a\u8005\uff0c\u62ff\u7559\u6709\u6848\u5e95\u7684\u7533\u8bf7\u4eba\u5f00\u5200\uff0c\u5e76\u53ef\u80fd\u4ea7\u751f\u989d\u5916\u5413\u963b\u6548\u679c\uff1b\u4e8c\u662f\u5ba1\u67e5\u5b98\u5fc5\u987b\u8bc1\u660e\u4e24\u6848\u76f8\u5173\uff08\u7533\u8bf7\uff09\u4e13\u5229\u8303\u56f4\u4e92\u76f8\u663e\u800c\u6613\u89c1\u3002<a href=\"#_ftn9\" name=\"_ftnref9\">[9]<\/a><\/p>\n<p><strong><span style=\"color: #0000ff;\">\u5907\u6ce8\uff1a<\/span><\/strong><\/p>\n<p><a href=\"#_ftnref1\" name=\"_ftn1\">[1]<\/a> USPTO convenes Appeals Review Panel to reconsider rejection of claims for obviousness-type double patenting and authorizes amicus briefing\uff0c\u8bf7\u89c1<a href=\"https:\/\/content.govdelivery.com\/accounts\/USPTO\/bulletins\/40ccd35\">https:\/\/content.govdelivery.com\/accounts\/USPTO\/bulletins\/40ccd35<\/a>\u3002Squires\u57282026\u5e749\u6708\u4e0b\u65ec\u752b\u5c31\u4efbUSPTO\u5c40\u957f\u4e00\u804c\uff0c\u5373\u66fe\u5229\u7528\u4e00\u822c\u7f55\u7528\u7684ARP\u673a\u5236\uff0c\u64a4\u9500PTAB\u5728<em>Ex parte Desjardins<\/em>\u539f\u8bc9\u613f\u7a0b\u5e8f\u65b0\u589e\u7684 35 U.S.C. 101\u6838\u9a73\u4e8b\u7531\uff0c11\u6708\u5e76\u6b63\u5f0f\u53d1\u5e03\u65b0\u95fb\u7a3f\uff0c\u6307\u5b9a\u8be5\u6848ARP\u51b3\u5b9a\u4f5c\u5148\u4f8b\u610f\u89c1<em>Ex parte Desjardins<\/em>, Appeal No. 2024-000567 (ARP Sept. 26, 2025) (precedential)\uff0cPTAB designates as precedential an Appeals Review Panel decision addressing AI under 35 U.S.C. \u00a7 101\uff0c\u8bf7\u89c1<a href=\"https:\/\/www.uspto.gov\/subscription-center\/2025\/ptab-designates-precedential-appeals-review-panel-decision\">https:\/\/www.uspto.gov\/subscription-center\/2025\/ptab-designates-precedential-appeals-review-panel-decision<\/a>\u3002<\/p>\n<p><a href=\"#_ftnref2\" name=\"_ftn2\">[2]<\/a> \u975e\u8303\u56f4\u5b8c\u5168\u91cd\u8fed\u7684\u91cd\u590d\u6388\u6743\u6838\u9a73\uff0c\u5148\u524dMPEP\u6539\u7248\u65f6\u7531\u663e\u800c\u6613\u89c1\u578b\u91cd\u590d\u6388\u6743\uff08Obviousness-type Double Patenting\uff1bMPEP\u7b80\u79f0ODP\uff09\uff0c\u6539\u79f0\u975e\u6cd5\u5b9a\u91cd\u590d\u6388\u6743\uff08Nonstatutory Double Patenting\uff1bMPEP\u5f53\u65f6\u7b80\u79f0NDP\uff09\uff0c2020\u5e74\u6539\u7248\u65f6\u53c8\u5c06\u7b80\u79f0\u7531NDP\u5fae\u8c03\u4e3aNSDP\uff0c\u672c\u6587\u64b0\u7a3f\u65f6\u7684\u6700\u65b0MPEP\u7248\u672cRev. 07.2022\uff0c\u4e5f\u4ecd\u79f0\u4e4b\u4e3a\u975e\u6cd5\u5b9a\u91cd\u590d\u6388\u6743\u3001NSDP\u3002<\/p>\n<p><a href=\"#_ftnref3\" name=\"_ftn3\">[3]<\/a> USPTO designates as precedential an Appeals Review Panel decision addressing obviousness-type double patenting\uff0c\u8bf7\u89c1<a href=\"https:\/\/content.govdelivery.com\/accounts\/USPTO\/bulletins\/423dd3c\">https:\/\/content.govdelivery.com\/accounts\/USPTO\/bulletins\/423dd3c<\/a>\u3002<\/p>\n<p><a href=\"#_ftnref4\" name=\"_ftn4\">[4]<\/a> <em>Allergan USA, Inc. v. MSN Laboratories Private Ltd.<\/em>, Fed. Cir. Case No. 24-1061 (August 13, 2024)\uff0c\u8bf7\u89c1<a href=\"https:\/\/www.cafc.uscourts.gov\/opinions-orders\/24-1061.OPINION.8-13-2024_2366074.pdf\">https:\/\/www.cafc.uscourts.gov\/opinions-orders\/24-1061.OPINION.8-13-2024_2366074.pdf<\/a>\u3002<\/p>\n<p><a href=\"#_ftnref5\" name=\"_ftn5\">[5]<\/a>\u90e8\u5206\u7f8e\u56fd\u4e13\u5229\u5f8b\u5e08\u63d0\u9192\uff0c\u4e0d\u540c\u6848\u4ef6\u7684\u7533\u8bf7\u4e13\u5229\u8303\u56f4\u5e94\u5c3d\u53ef\u80fd\u786e\u5b9e\u5207\u5206\u5f00\u6765\uff0c\u7533\u8bf7\u7b56\u7565\u5e94\u6ce8\u610f\u54ea\u6848\u5148\u7533\u8bf7\u3001\u54ea\u6848\u5148\u9886\u8bc1\uff0c\u5e76\u638c\u63e1\u540c\u65cf\u6848\u3001\u5173\u8054\u6848\u8fdb\u5ea6\u53ca\u6240\u6709\u6743\u6d41\u5411\u3002\u82e5Fed. Cir.\u672a\u6765\u786e\u8ba4\u53ef\u5355\u72ec\u4ee5\u907f\u514d\u91cd\u590d\u9a9a\u6270\u4e3a\u7531\u5e7f\u53d1OTDP\u6838\u9a73\uff0c\u7531\u4e8e\u4ee5TD\u514b\u670dOTDP\u6838\u9a73\u6709\u4e00\u5927\u524d\u63d0\uff0c\u5373\u88ab\u5ba1\u67e5\u6848\u4e0e\u5f15\u8bc1\u6848\u987b\u4e3a\u540c\u4e00\u5b9e\u4f53\u6240\u62e5\u6709\uff0c\u6bd4\u65b9\u4ea7\u5b66\u5408\u4f5c\u6216\u5171\u540c\u5f00\u53d1\u6848\u518d\u6709\u540e\u7eed\u53d1\u660e\u3001\u53d1\u660e\u4eba\u79bb\u804c\u540e\u53e6\u6709\u76f8\u5173\u53d1\u660e\uff0c\u90fd\u53ef\u80fd\u56e0\u65e0\u6cd5\u7b7e\u7f72TD\u800c\u884d\u751f\u989d\u5916\u95ee\u9898\uff1b\u4e14\u4ee5TD\u514b\u670d\u6838\u9a73\uff0c\u64cd\u4f5c\u5c3d\u7ba1\u76f8\u5bf9\u4e0d\u590d\u6742\uff0c\u53ef\u662f\u4f1a\u727a\u7272PTA\u5929\u6570\uff0c\u5e76\u5982\u5957\u4e0a\u4e00\u5177\u725b\u8f6d\uff0c\u884c\u4f7f\u4e13\u5229\u6743\u987b\u62d6\u7740\u5f15\u8bc1\u4e13\u5229\u4e00\u8d77\uff0c\u751a\u81f3\u6388\u6743\u8f6c\u8ba9\u7684\u5356\u76f8\u90fd\u4e0d\u514d\u53d7\u5230\u5f71\u54cd\u3002<\/p>\n<p><a href=\"#_ftnref6\" name=\"_ftn6\">[6]<\/a><em>In re Fallaux<\/em>, Fed. Cir. Case No. 2008-1545 (May 6, 2009)\uff0c\u8bf7\u89c1<a href=\"https:\/\/www.cafc.uscourts.gov\/opinions-orders\/08-1545.pdf\">https:\/\/www.cafc.uscourts.gov\/opinions-orders\/08-1545.pdf<\/a>\u3002<\/p>\n<p><a href=\"#_ftnref7\" name=\"_ftn7\">[7]<\/a> \u4f9d\u672c\u6848ARP\u51b3\u5b9a\u610f\u89c1\u4e66\u6ce83\uff0c\u4e13\u5229\u6743\u671f\u95f4\u7533\u8bf7\u65e5\u662f\u6307\u4e13\u5229\u6743\u671f\u95f4\u8d77\u59cb\u65e5\uff0c\u4e00\u822c\u5373\u6392\u9664\u4e00\u6848\u6240\u4e3b\u5f20\u7684\u5916\u56fd\u4f18\u5148\u6743\u53ca\u7f8e\u56fd\u6682\u65f6\u6848\u4f18\u5148\u6743\uff0c\u53d6\u5176\u6240\u4e3b\u5f20\u7684\u6700\u65e9\u7f8e\u56fd\u6b63\u5f0f\u6848\u7533\u8bf7\u65e5\u4e3a\u51c6\u3002<\/p>\n<p><a href=\"#_ftnref8\" name=\"_ftn8\">[8]<\/a> \u53ef\u53c2\u8003ARP\u610f\u89c1\u4e66\u7b2c26\u81f327\u9875\u4e3e\u4f8b\uff0c\u6bd4\u65b9\uff1a\u516c\u53f8X\u590d\u6570\u53d1\u660e\u4eba\u6709\u4e00\u53d1\u660e\u5148\u63d0\u4e13\u5229\u7533\u8bf7\u6848A\uff0c\u800c\u5728\u7533\u8bf7\u6848A\u5ba1\u67e5\u671f\u95f4\uff0c\u5176\u4e2d\u4e00\u540d\u53d1\u660e\u4eba\u8df3\u69fd\u5230\u516c\u53f8Y\uff0c\u4ea7\u751f\u7684\u540e\u51fa\u53d1\u660e\u4e5f\u63d0\u4e13\u5229\u7533\u8bf7\u6848B\uff0c\u800cB\u65e9\u4e00\u6b65\u9886\u8bc1\uff0c\u5f62\u6210\u516c\u53f8X\u5728\u5148\u7533\u8bf7\u6848A\u7684OTDP\u5f15\u8bc1\u6848\uff0c\u56e0A\u3001B\u4e24\u6848\u975e\u5c5e\u540c\u4e00\u5b9e\u4f53\u6240\u6709\uff0c\u516c\u53f8X\u5148\u7533\u8bf7\u6848A\u65e0\u6cd5\u76f4\u63a5\u4ee5TD\u6392\u9664\u76f8\u5173\u6838\u9a73\u3002<\/p>\n<p><a href=\"#_ftnref9\" name=\"_ftn9\">[9]<\/a> Two-way Test\uff0c\u53cc\u5411\u6d4b\u8bd5\u3002\u8fc7\u53bb\u4e0d\u5e38\u4f7f\u7528\uff0c\u4e3b\u8981\u5e94\u5bf9\u7279\u6b8a\u60c5\u51b5\uff0c\u4f8b\u5982Pre-URAA\u820a\u6848\u7d14\u56e0\u5b98\u65b9\u5ef6\u8aa4\u81f4\u5f8c\u7533\u8acb\u6848\u8f03\u5148\u7533\u8acb\u6848\u65e9\u9818\u8b49\u3002<strong>\u00a0<\/strong><\/p>\n<p><span style=\"color: #0000ff;\"><strong>\u5099\u8a3b\uff1a<\/strong><\/span><\/p>\n<p><a href=\"#_ftnref1\" name=\"_ftn1\">[1]<\/a> USPTO convenes Appeals Review Panel to reconsider rejection of claims for obviousness-type double patenting and authorizes amicus briefing\uff0c\u8acb\u898b<a href=\"https:\/\/content.govdelivery.com\/accounts\/USPTO\/bulletins\/40ccd35\">https:\/\/content.govdelivery.com\/accounts\/USPTO\/bulletins\/40ccd35<\/a>\u3002Squires\u57282026\u5e749\u6708\u4e0b\u65ec\u752b\u5c31\u4efbUSPTO\u5c40\u9577\u4e00\u8077\uff0c\u5373\u66fe\u5229\u7528\u4e00\u822c\u7f55\u7528\u7684ARP\u6a5f\u5236\uff0c\u64a4\u92b7PTAB\u5728<em>Ex parte Desjardins<\/em>\u539f\u8a34\u9858\u7a0b\u5e8f\u65b0\u589e\u7684 35 U.S.C. 101\u6838\u99c1\u4e8b\u7531\uff0c11\u6708\u4e26\u6b63\u5f0f\u767c\u5e03\u65b0\u805e\u7a3f\uff0c\u6307\u5b9a\u8a72\u6848ARP\u6c7a\u5b9a\u4f5c\u5148\u4f8b\u610f\u898b<em>Ex parte Desjardins<\/em>, Appeal No. 2024-000567 (ARP Sept. 26, 2025) (precedential)\uff0cPTAB designates as precedential an Appeals Review Panel decision addressing AI under 35 U.S.C. \u00a7 101\uff0c\u8acb\u898b<a href=\"https:\/\/www.uspto.gov\/subscription-center\/2025\/ptab-designates-precedential-appeals-review-panel-decision\">https:\/\/www.uspto.gov\/subscription-center\/2025\/ptab-designates-precedential-appeals-review-panel-decision<\/a>\u3002<\/p>\n<p><a href=\"#_ftnref2\" name=\"_ftn2\">[2]<\/a> \u975e\u7bc4\u570d\u5b8c\u5168\u91cd\u758a\u7684\u91cd\u8907\u6388\u6b0a\u6838\u99c1\uff0c\u5148\u524dMPEP\u6539\u7248\u6642\u7531\u986f\u800c\u6613\u898b\u578b\u91cd\u8907\u6388\u6b0a\uff08Obviousness-type Double Patenting\uff1bMPEP\u7c21\u7a31ODP\uff09\uff0c\u6539\u7a31\u975e\u6cd5\u5b9a\u91cd\u8907\u6388\u6b0a\uff08Nonstatutory Double Patenting\uff1bMPEP\u7576\u6642\u7c21\u7a31NDP\uff09\uff0c2020\u5e74\u6539\u7248\u6642\u53c8\u5c07\u7c21\u7a31\u7531NDP\u5fae\u8abf\u70baNSDP\uff0c\u672c\u6587\u64b0\u7a3f\u6642\u7684\u6700\u65b0MPEP\u7248\u672cRev. 07.2022\uff0c\u4e5f\u4ecd\u7a31\u4e4b\u70ba\u975e\u6cd5\u5b9a\u91cd\u8907\u6388\u6b0a\u3001NSDP\u3002<\/p>\n<p><a href=\"#_ftnref3\" name=\"_ftn3\">[3]<\/a> USPTO designates as precedential an Appeals Review Panel decision addressing obviousness-type double patenting\uff0c\u8acb\u898b<a href=\"https:\/\/content.govdelivery.com\/accounts\/USPTO\/bulletins\/423dd3c\">https:\/\/content.govdelivery.com\/accounts\/USPTO\/bulletins\/423dd3c<\/a>\u3002<\/p>\n<p><a href=\"#_ftnref4\" name=\"_ftn4\">[4]<\/a> <em>Allergan USA, Inc. v. MSN Laboratories Private Ltd.<\/em>, Fed. Cir. Case No. 24-1061 (August 13, 2024)\uff0c\u8acb\u898b<a href=\"https:\/\/www.cafc.uscourts.gov\/opinions-orders\/24-1061.OPINION.8-13-2024_2366074.pdf\">https:\/\/www.cafc.uscourts.gov\/opinions-orders\/24-1061.OPINION.8-13-2024_2366074.pdf<\/a>\u3002<\/p>\n<p><a href=\"#_ftnref5\" name=\"_ftn5\">[5]<\/a> \u90e8\u5206\u7f8e\u570b\u5c08\u5229\u5f8b\u5e2b\u63d0\u9192\uff0c\u4e0d\u540c\u6848\u4ef6\u7684\u7533\u8acb\u5c08\u5229\u7bc4\u570d\u61c9\u76e1\u53ef\u80fd\u78ba\u5be6\u5207\u5206\u958b\u4f86\uff0c\u7533\u8acb\u7b56\u7565\u61c9\u6ce8\u610f\u54ea\u6848\u5148\u7533\u8acb\u3001\u54ea\u6848\u5148\u9818\u8b49\uff0c\u4e26\u638c\u63e1\u540c\u65cf\u6848\u3001\u95dc\u806f\u6848\u9032\u5ea6\u53ca\u6240\u6709\u6b0a\u6d41\u5411\u3002\u82e5Fed. Cir.\u672a\u4f86\u78ba\u8a8d\u53ef\u55ae\u7368\u4ee5\u907f\u514d\u91cd\u8907\u9a37\u64fe\u70ba\u7531\u5ee3\u767cOTDP\u6838\u99c1\uff0c\u7531\u65bc\u4ee5TD\u514b\u670dOTDP\u6838\u99c1\u6709\u4e00\u5927\u524d\u63d0\uff0c\u5373\u88ab\u5be9\u67e5\u6848\u8207\u5f15\u8b49\u6848\u9808\u70ba\u540c\u4e00\u5be6\u9ad4\u6240\u64c1\u6709\uff0c\u6bd4\u65b9\u7522\u5b78\u5408\u4f5c\u6216\u5171\u540c\u958b\u767c\u6848\u518d\u6709\u5f8c\u7e8c\u767c\u660e\u3001\u767c\u660e\u4eba\u96e2\u8077\u5f8c\u53e6\u6709\u76f8\u95dc\u767c\u660e\uff0c\u90fd\u53ef\u80fd\u56e0\u7121\u6cd5\u7c3d\u7f72TD\u800c\u884d\u751f\u984d\u5916\u554f\u984c\uff1b\u4e14\u4ee5TD\u514b\u670d\u6838\u99c1\uff0c\u64cd\u4f5c\u5118\u7ba1\u76f8\u5c0d\u4e0d\u8907\u96dc\uff0c\u53ef\u662f\u6703\u72a7\u7272PTA\u5929\u6578\uff0c\u4e26\u5982\u5957\u4e0a\u4e00\u5177\u725b\u8edb\uff0c\u884c\u4f7f\u5c08\u5229\u6b0a\u9808\u62d6\u8457\u5f15\u8b49\u5c08\u5229\u4e00\u8d77\uff0c\u751a\u81f3\u6388\u6b0a\u8f49\u8b93\u7684\u8ce3\u76f8\u90fd\u4e0d\u514d\u53d7\u5230\u5f71\u97ff\u3002<\/p>\n<p><a href=\"#_ftnref6\" name=\"_ftn6\">[6]<\/a> <em>In re Fallaux<\/em>, Fed. Cir. Case No. 2008-1545 (May 6, 2009)\uff0c\u8acb\u898b<a href=\"https:\/\/www.cafc.uscourts.gov\/opinions-orders\/08-1545.pdf\">https:\/\/www.cafc.uscourts.gov\/opinions-orders\/08-1545.pdf<\/a>\u3002<\/p>\n<p><a href=\"#_ftnref7\" name=\"_ftn7\">[7]<\/a> \u4f9d\u672c\u6848ARP\u6c7a\u5b9a\u610f\u898b\u66f8\u8a3b3\uff0c\u5c08\u5229\u6b0a\u671f\u9593\u7533\u8acb\u65e5\u662f\u6307\u5c08\u5229\u6b0a\u671f\u9593\u8d77\u59cb\u65e5\uff0c\u4e00\u822c\u5373\u6392\u9664\u4e00\u6848\u6240\u4e3b\u5f35\u7684\u5916\u570b\u512a\u5148\u6b0a\u53ca\u7f8e\u570b\u66ab\u6642\u6848\u512a\u5148\u6b0a\uff0c\u53d6\u5176\u6240\u4e3b\u5f35\u7684\u6700\u65e9\u7f8e\u570b\u6b63\u5f0f\u6848\u7533\u8acb\u65e5\u70ba\u6e96\u3002<\/p>\n<p><a href=\"#_ftnref8\" name=\"_ftn8\">[8]<\/a> \u53ef\u53c3\u8003ARP\u610f\u898b\u66f8\u7b2c26\u81f327\u9801\u8209\u4f8b\uff0c\u6bd4\u65b9\uff1a\u516c\u53f8X\u8907\u6578\u767c\u660e\u4eba\u6709\u4e00\u767c\u660e\u5148\u63d0\u5c08\u5229\u7533\u8acb\u6848A\uff0c\u800c\u5728\u7533\u8acb\u6848A\u5be9\u67e5\u671f\u9593\uff0c\u5176\u4e2d\u4e00\u540d\u767c\u660e\u4eba\u8df3\u69fd\u5230\u516c\u53f8Y\uff0c\u7522\u751f\u7684\u5f8c\u51fa\u767c\u660e\u4e5f\u63d0\u5c08\u5229\u7533\u8acb\u6848B\uff0c\u800cB\u65e9\u4e00\u6b65\u9818\u8b49\uff0c\u5f62\u6210\u516c\u53f8X\u5728\u5148\u7533\u8acb\u6848A\u7684OTDP\u5f15\u8b49\u6848\uff0c\u56e0A\u3001B\u5169\u6848\u975e\u5c6c\u540c\u4e00\u5be6\u9ad4\u6240\u6709\uff0c\u516c\u53f8X\u5148\u7533\u8acb\u6848A\u7121\u6cd5\u76f4\u63a5\u4ee5TD\u6392\u9664\u76f8\u95dc\u6838\u99c1\u3002<\/p>\n<p><a href=\"#_ftnref9\" name=\"_ftn9\">[9]<\/a> Two-way Test\uff0c\u96d9\u5411\u6e2c\u8a66\u3002\u904e\u53bb\u4e0d\u5e38\u4f7f\u7528\uff0c\u4e3b\u8981\u61c9\u5c0d\u7279\u6b8a\u60c5\u6cc1\uff0c\u4f8b\u5982Pre-URAA\u820a\u6848\u7d14\u56e0\u5b98\u65b9\u5ef6\u8aa4\u81f4\u5f8c\u7533\u8acb\u6848\u8f03\u5148\u7533\u8acb\u6848\u65e9\u9818\u8b49\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u9ec4\u5170\u95f5\uff0f\u5317\u7f8e\u667a\u6743\u3000\u667a\u6743\u6cd5\u89c4\u7814\u7a76\u5458 USPTO\u72ed\u4e49\u89e3\u91caFed. Cir. Allergan\u6848\u4f8b\u5916\u539f\u5219\uff0c\u6307\u793a\u8be5\u5c40\u4eba [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":72286,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[263,283,253,256],"tags":[],"author_name1":[334],"class_list":{"0":"post-72311","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-263","8":"category-283","9":"category-253","10":"category-256","11":"author_name1--zh-hans"},"_links":{"self":[{"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/posts\/72311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/comments?post=72311"}],"version-history":[{"count":4,"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/posts\/72311\/revisions"}],"predecessor-version":[{"id":72395,"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/posts\/72311\/revisions\/72395"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/media\/72286"}],"wp:attachment":[{"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/media?parent=72311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/categories?post=72311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/tags?post=72311"},{"taxonomy":"author_name1","embeddable":true,"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/author_name1?post=72311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}